Esaote Unveils Cutting-Edge PAM Technology for Enhanced Urological Imaging at EAU 2026

Esaote's Innovative Contribution at EAU 2026: Introducing PAM Technology

Esaote Group, a distinguished Italian medical imaging leader, is making waves at the 41st Annual European Association of Urology (EAU) Congress held in London from March 13 to 16, 2026. The organization is showcasing its novel Prostate Attention Map (PAM) technology, along with the newly launched MyLab™E85 GTS ultrasound system and the MyLab™C30 GTS portable system.

Esaote's presence at the EAU Congress underscores its commitment to enhancing urological imaging and therapy solutions, especially as it pertains to prostate care. The PAM technology is cutting-edge, allowing for automatic analysis of multi-parametric MRI volumes of the prostate and assisting urologists in identifying suspicious regions. This capability is pivotal in refining both diagnosis and intervention guidance, ensuring that practitioners can make informed decisions rooted in precision.

Technological Innovations in Urology

The PAM technology is intricately integrated into Esaote's UroFusion software, which is specifically designed to enhance targeted biopsies of the prostate. According to Marta Daniel, Esaote’s Guided Therapy Product and Clinical Solutions Manager, the software streamlines the workflow of urologists. By implementing artificial intelligence, it provides a seamless experience that parallels the time of standard biopsies but with elevated accuracy and confidence in the outcomes.

During the congress, Esaote is also engaged in hands-on sessions for TP Biopsy and MRI-US Fusion, allowing attendees to gain first-hand experience with the latest advancements in urology imaging. This interaction not only showcases the technology but also emphasizes Esaote's dedication to education within the medical community.

Commitment to Clinical Excellence

Esaote's unveiling of PAM technology is part of a broader strategy to fortify its portfolio of Guided Therapy Solutions (GTS). It highlights the company's resolve to deliver reliable, intelligent, and clinically pertinent imaging solutions. As urology continues to advance, technologies like PAM are crucial for supporting healthcare professionals in providing top-tier care.

With a strong presence in more than 100 countries and with numerous employees engaged in research and production across Italy and the Netherlands, Esaote is poised to continue its legacy of innovation in medical imaging.

A Broader Impact on Medical Imaging

Esaote is not just a leader in ultrasound imaging but also excels in dedicated magnetic resonance imaging and medical IT solutions. As of the end of 2025, the company boasted a workforce of 1,300 individuals, with a significant portion situated in Italy. The upcoming technologies showcased at EAU 2026 will further enhance their repertoire and service offerings in high-quality imaging and patient care.

Conclusion

Esaote Group is setting a benchmark in medical imaging technology with its introduction of PAM technology at EAU 2026. This innovation promises to elevate precision in urological imaging, fundamentally changing how urologists conduct their practices. It is further evidence of Esaote's ongoing commitment to advancing healthcare solutions that improve patient outcomes.